ACTRN12617000870358终止未知
Does Antipsychotic Dose Reduction in combination with Evidence-Based Intensive Recovery Treatment (EBIRT) Lead to Better Functional Recovery in First Episode Psychosis: A Randomised Controlled Trial
Orygen, the National Centre of Excellence in Youth Mental Health0 个研究点目标入组 44 人开始时间: 2017年6月15日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 终止
- 发起方
- 入组人数
- 44
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomised controlled trial
- 主要目的
- Treatment
入排标准
- 年龄范围
- 15 Years 至 25 Years（—）
- 性别
- All
入选标准
- •A participant will be considered eligible for inclusion in this study if all of the following criteria apply:
- •1.Current client of EPPIC
- •2.A confirmed diagnosis of first episode of a DSM-5 psychotic disorder or mood disorder with psychotic features as determined by the Structured Clinical Interview for DSM-5 Axis I Disorders, patient version (SCID-RV);
- •3.Aged 15-25 years (inclusive).
- •4. greater than or equal to 3 months of remission on positive symptoms of psychosis in the first year of antipsychotic treatment at EPPIC (a score of greater than or equal to 3 (mild) on the hallucinations, unusual thought disorder, conceptual disorganisation, and suspiciousness subscale items of the Brief Psychiatric Rating Scale (BPRS) for the past two weeks and a score greater than or equal to 3 on the hallucinations, unusual thought content, conceptual disorganisation, and suspiciousness subscales of the BRPS for the past 3 months based on a systematic clinical file review and collateral information collected from the participant’s treating team in EPPIC as needed).
- •5.Low suicidality defined as a score of 4 or below on the BPRS sustained for the past 1-month period from baseline.
- •6.The young person is willing for their carer to be informed about the study and will have at least weekly contact with their carer.
- •7. Ability to provide written informed consent.
- •Where participants are under 18 years of age, consent will also be obtained from the participant’s parent or legal guardian. The parent or legal guardian and participant will both be required to sign a consent form.
- •Healthy controls will be aged 15-25 years (inclusive), who are able to attend appointments in Parkville, and have no self-reported history of mental illness, antipsychotic medication treatment, or neurological disorder.
排除标准
- •FEP Exclusion Criteria
- •Participants who meet any of the following criteria will not be eligible for participation in this study:
- •1.A documented history of an intellectual disability or IQ <70
- •2.Inability to converse in or read English
- •3.Women who are currently pregnant or breastfeeding
- •4.Neurological disorder
- •Health Controls Exclusion Criteria:
- •Healthy controls will have no self-reported history of mental illness (including no history of a psychotic disorder), anti psychotic medication treatment or neurological disorder.
研究者
相似试验
已完成
不适用
Model-Guided Antipsychotic Dose Reduction in Schizophrenia: A Single-Blind Randomized Controlled TrialSchizophreniaJPRN-UMIN000014976Minamihanno Hospital60
已完成
不适用
Effects of Antipsychotic Reduction on Negative Subjective Experience and Cognitive FunctioschizophreniaJPRN-UMIN000001834Keio University, School of Medicine100
已完成
不适用
A randomized single-blind trial of the therapeutic effects and safety of halved dose antipsychotics for treating relapse in patients with schizophrenia receiving high dose antipsychotic therapyschizophreniaJPRN-UMIN000047785Showa University54
进行中（未招募）
1 期
ANDREA-LD; Anti-psychotic drug reduction in primary care for adults with Learning disabilitiesEUCTR2013-000389-12-GBCardiff University22
已完成
不适用
The Treatment Efficacy of Combination Atypical Antipsychotics With Sertraline in Patients With SchizophreniaSchizophreniaNCT04076371Beijing HuiLongGuan Hospital1,640